Preferred Label : oxadiazoles;
MeSH definition : Compounds containing five-membered heteroaromatic rings containing two carbons, two
nitrogens, and one oxygen atom which exist in various regioisomeric forms.;
MeSH synonym : Oxadiazole;
Is substance : O;
Origin ID : D010069;
UMLS CUI : C0029984;
Allowable qualifiers
Record concept(s)
Related MeSH Supplementary Concept(s)
- (2''S,3aR,6S,7aR)-3''-acetyl-3a,7a-dihydro-2,2,2'-2',-tetramethyl-5'-(4-bromophenyl)-spiro(spiro(1,3-dioxolo(4,5-D)-pyrane-6(7H),5'(4'H)-1',3'-dioxolo)-7(6H),2''(3''H)-(1,3,4)-oxadiazole) [MeSH Supplementary Concept]
- 1,3,4,5,6,7,8,10-octahydro-14-hydroxy-12-methoxy-11-methyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-6-thioxo-9,2,5-benzoxanthiaazacyclododecine-10-one [MeSH Supplementary Concept]
- 1,3,4,5,6,7,8,9,10,12-decahydro-16-hydroxy-14-methoxy-13-methyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-6-thioxo-11,2,5-benzoxathiaazacyclotetradecine-12-one [MeSH Supplementary Concept]
- 2NBDG [MeSH Supplementary Concept]
- 5,5'-(5,5'-((1R,2R)-1,2-dihydroxyethane-1,2-diyl)bis(1,3,4-oxadiazole-5,2-diyl))dibenzene-1,2,3-triol [MeSH Supplementary Concept]
- AM-0902 [MeSH Supplementary Concept]
- ASP2151 [MeSH Supplementary Concept]
- ASP4058 [MeSH Supplementary Concept]
- AT-308 [MeSH Supplementary Concept]
- AZD1979 [MeSH Supplementary Concept]
- AZD3988 [MeSH Supplementary Concept]
- AZD6538 [MeSH Supplementary Concept]
- AZD8529 [MeSH Supplementary Concept]
- AZD8835 [MeSH Supplementary Concept]
- AZD9272 [MeSH Supplementary Concept]
- BFD-22 [MeSH Supplementary Concept]
- BOXD-T3 [MeSH Supplementary Concept]
- CFM6104 [MeSH Supplementary Concept]
- CPNBD [MeSH Supplementary Concept]
- CS-2100 [MeSH Supplementary Concept]
- DA-1241 [MeSH Supplementary Concept]
- DEPO [MeSH Supplementary Concept]
- F 96982 [MeSH Supplementary Concept]
- HCK-123 [MeSH Supplementary Concept]
- JTZ132 [MeSH Supplementary Concept]
- JZP327A [MeSH Supplementary Concept]
- KKL-35 [MeSH Supplementary Concept]
- KPT-251 [MeSH Supplementary Concept]
- LCX001 [MeSH Supplementary Concept]
- MC3181 [MeSH Supplementary Concept]
- MK 6892 [MeSH Supplementary Concept]
- MO 113 [MeSH Supplementary Concept]
- NIP 121 [MeSH Supplementary Concept]
- NS 2028 [MeSH Supplementary Concept]
- NS14490 [MeSH Supplementary Concept]
- NV848 [MeSH Supplementary Concept]
- NV914 [MeSH Supplementary Concept]
- NV930 [MeSH Supplementary Concept]
- PI-1840 [MeSH Supplementary Concept]
- QT-011 [MeSH Supplementary Concept]
- RAD140 [MeSH Supplementary Concept]
- SEW2871 [MeSH Supplementary Concept]
- SM 6586 [MeSH Supplementary Concept]
- TCS2002 [MeSH Supplementary Concept]
- TMP195 [MeSH Supplementary Concept]
- U 79098 [MeSH Supplementary Concept]
- U 80447 [MeSH Supplementary Concept]
- U 82217 [MeSH Supplementary Concept]
- U 82249 [MeSH Supplementary Concept]
- U 90042 [MeSH Supplementary Concept]
- Wd 67-2 [MeSH Supplementary Concept]
- Wf-516 [MeSH Supplementary Concept]
- XI-006 [MeSH Supplementary Concept]
- YM 099 [MeSH Supplementary Concept]
- YM 440 [MeSH Supplementary Concept]
- vadrine [MeSH Supplementary Concept]
Semantic type(s)
Compounds containing five-membered heteroaromatic rings containing two carbons, two
nitrogens, and one oxygen atom which exist in various regioisomeric forms.
https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ozanimod
ozanimod
ozanimod
adult
multiple sclerosis, relapsing-remitting
administration, oral
Sphingosine-1-Phosphate receptors
product surveillance, postmarketing
aged
drug interactions
contraception
pregnancy
breast feeding
drug evaluation, preclinical
Product containing precisely ozanimod (as ozanimod hydrochloride) 460 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 230 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 920 microgram/1
each conventional release oral capsule (clinical drug)
receptors, lysosphingolipid
indans
oxadiazoles
indans
oxadiazoles
---
https://www.has-sante.fr/jcms/p_3226174/fr/zeposia
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
ozanimod
ozanimod
ozanimod
adult
multiple sclerosis, relapsing-remitting
administration, oral
Sphingosine-1-Phosphate receptors
Product containing precisely ozanimod (as ozanimod hydrochloride) 230 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 460 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 920 microgram/1
each conventional release oral capsule (clinical drug)
evaluation of the transparency committee
receptors, lysosphingolipid
indans
oxadiazoles
indans
oxadiazoles
---
https://www.has-sante.fr/jcms/p_3118134/fr/translarna
2019
false
false
false
France
ataluren
treatment outcome
insurance, health, reimbursement
administration, oral
ataluren
muscular dystrophy, duchenne
child
evaluation of the transparency committee
oxadiazoles
---
https://www.has-sante.fr/portail/jcms/c_2904836/fr/ongentys
https://www.has-sante.fr/portail/jcms/c_2904836/fr/ongentys-opicapone-anti-parkinsoniens-dopaminergiques
2019
false
true
false
false
France
French
treatment outcome
anti-parkinson drugs
adult
parkinson disease
drug therapy, combination
Motor fluctuations
administration, oral
Catechol O-Methyltransferase Inhibitors
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
antiparkinson agents
levodopa
DOPA Decarboxylase Inhibitors
Aromatic Amino Acid Decarboxylase Inhibitors
opicapone
oxadiazoles
---
https://www.has-sante.fr/portail/jcms/c_2779824/fr/translarna
https://www.has-sante.fr/portail/jcms/c_2779824/fr/translarna-ataluren-arn-interferant
2017
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
guidelines for drug use
ataluren
ataluren
orphan drug production
muscular dystrophy, duchenne
child
adult
adolescent
rna interference
ataluren
dystrophin
mutation, nonsense
oxadiazoles
oxadiazoles
codon, nonsense
---
https://www.ema.europa.eu/medicines/human/EPAR/Ongentys
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
opicapone
oxadiazoles
drug approval
europe
treatment outcome
anti-parkinson drugs
product surveillance, postmarketing
adult
parkinson disease
drug therapy, combination
Motor fluctuations
administration, oral
drug interactions
pregnancy
breast feeding
Catechol O-Methyltransferase Inhibitors
Catechol O-Methyltransferase Inhibitors
opicapone
oxadiazoles
---
https://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-10-fra.php#a19
2016
false
false
false
Canada
French
azilsartan medoxomil and diuretics
drug combinations
chlorthalidone
azilsartan medoxomil
hyponatremia
pharmacovigilance note
benzimidazoles
oxadiazoles
---
http://www.has-sante.fr/portail/jcms/c_2009663/fr/translarna
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
guidelines for drug use
ataluren
ataluren
rare diseases
orphan drug production
muscular dystrophy, duchenne
child
adult
adolescent
rna interference
ataluren
oxadiazoles
oxadiazoles
---
https://www.ema.europa.eu/medicines/human/EPAR/Translarna
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
orphan drug production
ataluren
ataluren
muscular dystrophy, duchenne
muscular dystrophy, duchenne
mutation, nonsense
codon, nonsense
rare diseases
administration, oral
dystrophin
DMD protein, human
risk assessment
product surveillance, postmarketing
drug monitoring
child
adolescent
adult
genetic testing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ataluren
oxadiazoles
oxadiazoles
---